ENA Respiratory has started dosing participants in its phase 2 community study of INNA‑051, a dry‑powder nasal spray designed to strengthen the body’s natural antiviral defences and reduce the impact ...

CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...

Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting ...

Corcept Therapeutics, a pharmaceutical company specialising in cortisol-modulating medications, has announced that its ...

Gedeon Richter UK has assumed full marketing and distribution responsibilities for the neuropsychiatry medicine cariprazine ...

Astellas Pharma has announced that the Scottish Medicines Consortium has accepted zolbetuximab for use on the NHS in Scotland ...

Nxera Pharma has reported encouraging top-line data from a phase 3 clinical trial of its insomnia treatment daridorexant in ...

ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

Argo Biopharma has announced that the first patient has been dosed in a global phase 2b clinical trial of BW‑20829, an siRNA therapy being evaluated in adults with elevated lipoprotein (a) and ...

Venner Shipley, an intellectual property (IP) law firm with focuses including life sciences, pharmaceuticals and medtech, has ...

ARTCLINE, a biomedical company specialising in the development of immune cell treatments for septic shock, has announced the ...